Litcius/Paper detail

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial

Magdalena E. Sobieszczyk, Sharon Mannheimer, Carmen A. Paez, Chenchen Yu, Theresa Gamble, Deborah Theodore, Wairimu Chege, Margaret Yacovone, Brett Hanscom, Jack Heptinstall, Kelly E. Seaton, Lily Zhang, Maurine D. Miner, Amanda Eaton, Joshua A. Weiner, Kenneth H. Mayer, Spyros A. Kalams, Kathryn E. Stephenson, Boris Jülg, Marina Caskey, Michel C. Nussenzweig, Lúcio Gama, Dan H. Barouch, Margaret E. Ackerman, Georgia D. Tomaras, Yunda Huang, David C. Montefiori

2023The Lancet HIV31 citationsDOIOpen Access PDF

Topics & Concepts

PharmacokineticsMedicineTolerabilityAntibodyNeutralizationAdverse effectPopulationEpitopePharmacologyInternal medicineMonoclonal antibodyHuman immunodeficiency virus (HIV)Clinical trialImmunologyEnvironmental healthHIV Research and TreatmentHIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial | Litcius